Drug intelligence / Profile preview

APIRx-1702

Development stage: Preclinical
Lead developer: Incannex Healthcare
Modality: Small Molecules
Administration: Ophthalmic

Overview

**APIRx-1702** is a preclinical ophthalmic drug candidate developed using APIRx's patented cannabinoid delivery technologies, such as sustained-release transconjunctival formulations like OphtoCann™ or CannBleph™, targeting **dry eye syndrome**. It leverages cannabinoids for potential anti-inflammatory and neuroprotective effects in ocular tissues, addressing a global market projected at $6.6B by 2027. The program stems from APIRx Pharmaceuticals, acquired by Incannex Healthcare in 2022, with pre-IND completed in the Netherlands and Switzerland, and Orphan Drug Designation granted; in vitro studies support proof-of-concept, positioning it for Phase 1 advancement.

Targets

CB (Cannabinoid receptors)

Beyond the preview

Go deeper on APIRx-1702.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on APIRx-1702.

Explore the full profile